Introduction
Transplant-associated microangiopathy (TAM) is an occasional but life-threatening complication after allogeneic hematopoietic SCT (allo-HSCT). [1] [2] [3] Diagnostic criteria have been proposed by two large groups. One of which is the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Toxicity Committee Consensus in 2005. 4 In their criteria, TAM was described as a syndrome presenting renal dysfunction, neurological dysfunction and hemolysis with schistocytes and elevated lactate dehydrogenase (LDH). In the criteria proposed by the European Group for Blood and Marrow Transplantation (EBMT) in 2007, 5 TAM was defined as a syndrome presenting more than 4% of schistocytes, thrombocytopenia, elevated LDH, anemia and decreased haptoglobin. Although its etiology and pathogenesis have not been fully clarified, endothelial damage induced by multiple factors, such as conditioning regimens, GVHD, immunosuppressants and infection, contributes to its development. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Management of TAM is supportive, and withdrawal or decreasing the dose of calcineurin inhibitors is suggested as the first step in the treatment. 4, 10 Severe diarrhea is a serious symptom after allo-HSCT. Acute GVHD and intestinal infection have been the major causes of diarrhea after the resolution of regimen-related intestinal toxicity. 16 Except for infection, severe diarrhea has been treated as intestinal GVHD in many occasions. However, such diarrhea is often refractory to treatment for acute GVHD. 17, 18 As one reason for refractoriness to immunosuppressive treatment, we reported for the first time that intestinal tract was also a target organ for TAM. 19 Intestinal TAM (i-TAM) developed as ischemic colitis in some of the patients suffering from severe diarrhea after transplantation. Although clinical symptoms such as abdominal pain and severe and bloody diarrhea resemble those caused by intestinal GVHD, i-TAM can be diagnosed histopathologically by means of colonoscopic biopsies even for patients who do not meet the clinical criteria of systemic TAM. 19 Diagnosis of i-TAM is important because tapering of immunosuppressants may result in the resolution of intestinal symptoms and better survival. 19 To clarify more detailed clinicopathological manifestations of i-TAM and its therapeutic strategy with a larger number of patients, we conducted a retrospective multicenter study in the Nagoya Blood and Marrow Transplantation Group.
Patients and methods

Patients
A total of 886 patients received allo-SCT in the Nagoya Blood and Marrow Transplantation Group from 1997 to 2006. Of these, 87 patients (10%) who received colonoscopic biopsy within 5 months after engraftment were evaluated. This retrospective study was approved by the ethics committee at Nagoya University Hospital.
Histopathological diagnosis
All specimens were fixed in formalin solution and embedded in paraffin. Sections were stained with hematoxylin-eosin. Immunostainings of CD34 (Novocatra, Newcastle, UK), CD8 (Novocatra) and CMV (DAKO, Copenhagen, Denmark) were performed using paraffin sections by Envision methods (DAKO) according to the manufacturer's instructions. Specimens were reviewed retrospectively by four expert pathologists in a blinded manner (MI, MF, RI and NH), and diagnosis was made according to the consensus among these pathologists.
Histopathological diagnosis of i-TAM was made by the presence of microangiopathy with ischemic (noninflammatory) crypt loss ( Figure 1 ). Microangiopathy was confirmed by hematoxylin-eosin staining and CD34 immunostaining. The clues for endothelial injury are swollen endothelial cells and denuded endothelial cells. 20 Ischemic changes followed by microangiopathy included individual non-inflammatory crypt degeneration with detachment and apoptosis of epithelial cells, wedge-shaped segmental injury and interstitial edema with hemorrhage or fragmented RBCs. Incomplete regeneration and residual neuroendocrine cells were also indicators of ischemic tissue damage. To identify residual neuroendocrine cells, either Grimelius staining or immunostaining for chromogranin A, CD56 or synaptophysin was used. Plt thrombi were not necessarily required for diagnosis because, unlike thrombotic thrombocytopenic purpura (TTP), systemic microthrombus formation has not been shown to play an essential role in TAM. 5, 7, 20 Histopathological diagnosis of GVHD was based on apoptosis associated with intraepithelial lymphocytosis of cytotoxic T cells confirmed by CD8 immunostaining. Diagnosis of CMV colitis was based on intranuclear and intracytoplasmic amphophilic viral inclusion body and confirmed by positive CMV immunostaining.
Clinical data assessment
Retrospective chart reviews were performed to collect clinical data including (1) patient background (age, sex, disease, risk, donor type, graft source, HLA and ABO compatibilities, conditioning regimen, GVHD prophylaxis, duration from transplantation to the onset of diarrhea and duration from the onset of diarrhea to biopsy); (2) doses of immunosuppressants before and after the onset of diarrhea; (3) laboratory findings (LDH, schistocytes, haptoglobin, direct and indirect Coombs tests, blood urea nitrogen and serum creatinine); (4) coexistent symptoms (abdominal pain, bloody diarrhea and neurological dysfunction); (5) skin or liver GVHD at biopsy; and (6) safety of colonoscopic biopsy (plt at biopsy and procedure-associated complications). Chronic GVHD was evaluated in patients surviving beyond day 100 and was classified as limited or extensive according to the Seattle criteria. 21 Diagnosis of systemic TAM was made by BMT CTN criteria and modified EBMT criteria (more than two schistocytes per high-power field on peripheral smear, thrombocytopenia, elevated LDH and decreased haptoglobin).
Treatment for diarrhea was determined by the physician in charge at the time. Accordingly, patients could be divided into four groups by the way of immunosuppressant use (steroid, CYA and tacrolimus) 1 week before and after the onset of diarrhea: intensified-intensified (I-I) group, intensified-not intensified (I-N) group, not intensifiedintensified (N-I) group and not intensified-not intensified (N-N) group. 'Intensified' was defined by increments of any immunosuppressant, and 'not intensified' was defined by maintenance or tapering of all immunosuppressants.
Statistical analysis
The aim of this study was to evaluate more detailed clinicopathological manifestations of i-TAM and safety 
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Median age was 41 years. More male patients were included. Diseases were heterogenous hematological malignancies. Disease risk was standard in 33 patients and high in 54 patients; standard risk included acute leukemia and lymphoma in the first and second remission, CML in chronic phase and myelodysplastic syndrome in refractory anemia with or without ringed sideroblasts, whereas high risk included others. Donor was related in 32 patients and unrelated in 55 patients. Graft source was BM in 69 patients, PBSCs in 13 patients and cord blood in 5 patients. HLA was genotypically matched at A, B and DRB1 loci in 45 patients and mismatched in 42 patients (1 Ag mismatch at class I locus (n ¼ 13), 1 serological Ag mismatch at DRB1 locus (n ¼ 12), 1 genotypical Ag mismatch at DRB1 locus (n ¼ 9) and 2 Ag mismatches (n ¼ 8)). ABO was matched in 41 patients and mismatched in 46 patients. Conditioning regimen was myeloablative in 79 patients and non-myeloablative in 8 patients. Tacrolimus was used as GVHD prophylaxis in 59 patients and CYA in 28 patients. Median duration from transplantation to the onset of diarrhea was 32 days (range: 9-130 days) and that from the onset of diarrhea to biopsy was 12 days (range: 0-74 days).
Safety of colonoscopic biopsy
A total colonoscopic exam was performed in all patients.
No procedure-associated complications developed with plt transfusion for 30 patients, although plt at biopsy was less than 2 Â 10 10 /l in 12 patients.
Histopathological diagnosis and findings
Histopathological diagnosis in each patient is summarized in Figure 2 . i-TAM was confirmed in 80 patients (92%). GVHD was confirmed in 26 patients (30%) and was coexistent with i-TAM in 23 patients. The incidence of histopathological GVHD was lower among patients without steroid at biopsy than among those with steroid at biopsy, although the difference was not statistically significant (24 vs 38%; P ¼ 0.24). CMV was confirmed in 17 patients (20%). Findings were nonspecific in two patients.
Histopathological findings of i-TAM included microangiopathy with crypt loss (100%), interstitial edema with hemorrhage with or without fragmented RBCs (39%), crypt degeneration with detachment and/or apoptotic epithelial cells (93%), residual neuroendocrine cells (43%) and plt thrombi (30%) ( Table 2 ). The affected sites of the i-TAM, intestinal transplant-associated microangiopathy.
Intestinal TAM in allo-SCT Y Inamoto et al intestine were terminal ileum (90%), ascending colon (79%), transverse colon (83%), descending colon (77%), sigmoid colon (73%) and rectum (73%). The affected pattern was regional in 33% of patients and diffuse in 67% of the patients (Table 3) .
Clinical manifestations
The median maximal amount of diarrhea was 2 l/day (range: 130-5600 ml/day). Skin and/or liver GVHD before the onset of diarrhea was observed in 50 patients. Abdominal pain and bloody diarrhea at biopsy were observed in 70 and 26 patients, respectively. Veno-occlusive disease (VOD) was observed in six patients. Renal or neurological dysfunction was observed in 13 patients. Prolonged or progressive thrombocytopenia (plt count less than 5 Â 10 10 /l) and schistocytes on peripheral smear were observed in 51 and 40 patients, respectively. LDH was persistently elevated above the baseline value in 57 patients. Haptoglobin was decreased in 33 of 64 patients (no data available in 23 patients). There were no patients with positive direct or indirect Coombs tests. In this study, the numbers of patients fulfilling the diagnostic criteria of systemic TAM defined by BMT CTN and modified EBMT were 10 and 12, respectively. Comparison of clinical manifestations between patients with i-TAM and those without i-TAM demonstrated that massive diarrhea, abdominal pain, VOD and neurological dysfunction were observed more frequently among patients with i-TAM (Table 4) .
Clinical outcome OS after biopsy among 80 patients with i-TAM was 30% at 2 years. Diarrhea resolved in 51 patients, but NRM was as high as 33% among them and the relapse rate of the underlying disease was 27%. The causes of NRM in these patients were infection (n ¼ 8), systemic TAM (n ¼ 3), chronic GVHD (n ¼ 3), bronchiolitis obliterans-organizing pneumonia (n ¼ 1), VOD (n ¼ 1) and late graft failure (n ¼ 1). NRM increased significantly to 72% in patients without resolution of diarrhea (P ¼ 0.001). Their relapse rate of the underlying disease was 21%. One patient is alive with persistent diarrhea at 2 years and 5 months after transplantation. The causes of NRM in these patients were i-TAM (n ¼ 12), infection (n ¼ 4), interstitial pneumonia (n ¼ 3), VOD (n ¼ 1) and chronic GVHD (n ¼ 1). The cumulative incidence of chronic GVHD was 58% in 71 evaluable patients. Of 36 patients with chronic GVHD, 4 had the limited and 32 the extensive type.
The impact of treatment on clinical outcome
Among 80 patients with i-TAM, 33 received steroid therapy at biopsy. Before the onset of diarrhea, immunosuppressants were intensified in 30 patients and maintained in 50 patients. After the onset of diarrhea, immunosuppressants were intensified in 23 patients and maintained or tapered in 57 patients. Accordingly, I-I group included 6 patients, I-N group 24 patients, N-I group 17 patients and N-N group 33 patients. Resolution rates of diarrhea in each group were 50, 67, 65 and 64%, respectively (P ¼ 0.91).
Rates of NRM at 4 years in each group were 100, 79, 52 and 25%, respectively (P ¼ 0.0001; Figure 3 ). Subgroup analyses of the patients with i-TAM alone (n ¼ 44) and those with i-TAM and histopathological GVHD (n ¼ 21) also demonstrated similar results among the four groups (P ¼ 0.0019 and P ¼ 0.0005, respectively). After the onset of diarrhea, deterioration of skin or liver GVHD was observed in only 2 of 57 patients (3.5%) in the 'not intensified' group. After the onset of diarrhea, the incidence of chronic GVHD was higher in 'intensified' group than in Table 2 Histopathological findings of i-TAM Even adjusted by the use of steroid at biopsy, the absence of histopathological GVHD remained a significant factor (HR 2.9; CI 1.3-6.4; P ¼ 0.011) ( Table 5) .
Discussion
This study demonstrated that i-TAM was a major histopathological diagnosis in patients with severe diarrhea after allo-HSCT, comprising 92% of the patients. i-TAM was a major cause of NRM (57%) in patients without resolution of diarrhea. Massive refractory diarrhea (particularly more than 2 l/day) was a manifestation of i-TAM.
Abdominal pain similar to ischemic colitis was a frequent symptom of i-TAM as we have reported earlier. 19 VOD and neurological dysfunction were observed only among patients with i-TAM, suggesting their relation to this complication.
Sternberg et al. 20 described in the pathology textbook that thrombi might or might not be seen in thrombotic microangiopathies and there was thickening and/or thrombosis of arterioles. Recently, Ruutu et al. 5 described that the Working Group wanted to avoid the word thrombotic, as systemic microthrombus formation had not been shown to play an essential role in TAM, contrary to de novo TTP. Although some investigators believe that plt thrombi are the main features of TAM, the main feature of TAM is microangiopathy. In addition, sampling errors are possible in detecting plt thrombi. Therefore, thrombi are not necessary for the diagnosis of i-TAM, and we use the term TAM instead of TMA (thrombotic microangiopathy). It is interesting to note that the ileum was affected most frequently. Intestinal ischemia was reported as a significant early postoperative complication after renal transplantation, and the most common sites were the terminal ileum c Adjusted by the use of steroid at biopsy, this factor remained significant (hazard ratio 2.9; CI 1.3-6.4; P ¼ 0.011).
Intestinal TAM in allo-SCT Y Inamoto et al and ascending colon. 22 Its mechanism is multifactorial, but the use of combination immunosuppressive agents in the early period is one of the causes. 22 Ischemic colitis with a preference for the terminal ileum might be a notable complication associated with transplantation.
Most patients were clinically diagnosed with intestinal GVHD, but apoptosis with intraepithelial lymphocytosis, which is a histopathological evidence of GVHD, was confirmed in only 30% of the patients. Although the use of steroid at biopsy may contribute to an underestimation of histopathological GVHD, such an underestimation is unlikely because histopathological GVHD was confirmed less frequently among patients without steroid at biopsy than among patients with steroid at biopsy. Interestingly, the absence of histopathological GVHD resulted in a higher NRM. Even adjusted with the use of steroid at biopsy, the absence of histopathological GVHD still remained a significant factor. This suggests that histopathological GVHD can be improved with immunosuppressive treatment, whereas i-TAM is refractory to treatment because microangiopathy is unlikely to improve with immunosuppressants.
The central nervous system and kidney are involved independently by TAM, which is known as nephrotoxicity or neurotoxicity with microangiopathic hemolytic anemia. 2 Likewise, the intestine was involved independently despite the absence of systemic TAM. However, the proposed criteria for systemic TAM by two groups 4, 5 were not sufficient to make a diagnosis of i-TAM, because less than 15% of the patients fulfilled these criteria. The low matching rates of i-TAM and systemic TAM defined by the international panels' criteria suggest that systemic symptoms such as renal or neurological dysfunction, thrombocytopenia, schistocyte, elevated LDH and decreased haptoglobin have limitations for the diagnosis of i-TAM, and colonoscopic biopsy is the most reliable diagnostic method. i-TAM is a novel concept that cannot be diagnosed by the current scheme of transplant medicine. Other biomarkers of i-TAM are to be sought in the future.
The vascular endothelial damage of calcineurin inhibitors and steroid is one of the most important factors for the onset and deterioration of systemic TAM. 15 Several reports have documented an increased incidence of systemic TAM with sirolimus in combination with other calcineurin inhibitors. 23, 24 Systemic TAM resolved with discontinuation of calcineurin inhibitors in most cases. In addition, we recently established a rat model of intestinal microangiopathy induced by tacrolimus alone. 25 The pathology was consistent with human i-TAM after allo-HSCT, and rats recovered from microangiopathy after withdrawal of tacrolimus. Therefore, we hypothesized that 'not intensified' strategy for i-TAM would minimize drug-induced endothelial damage and improve outcome, and divided patients into four groups according to the way of immunosuppressant use. The fact that resolution of diarrhea was achieved without intensification of immunosuppressants is of considerable interest and suggests that many cases of refractory colitis after allo-HSCT are due to i-TAM rather than GVHD. Figure 2 does not mean the overlap of entities but instead the overlap of histopathological diagnosis. We believe that i-TAM has a wide spectrum from i-TAM only to i-TAM and GVHD/CMV. Even limited to the 21 patients with histopathological GVHD, the 'not intensified' strategy improved outcome. If these patients had only GVHD, the results were rather paradoxical. Their therapeutic response suggested a need for a uniform treatment strategy.
Vascular endothelial cells may be targets in acute GVHD, but they were reported to escape an attack by cytotoxic T cells due to their impaired capacity to present antigenic peptides. 26 A French group reported that vascular endothelial cells in intestine could be targets of alloimmune reactions, 27 but they did not recognize that T cells were almost absent histopathologically when diarrhea became refractory. Their histopathological features were consistent with i-TAM. Even if therapy for acute GVHD was intensified for their cases, the outcome would not be improved. When a diagnosis of i-TAM is made, avoiding intensification of immunosuppressants until the resolution of i-TAM will improve diarrhea and the transplant outcome. Avoiding intensification may cause deterioration of GVHD, but only 3.5% of the patients experienced deterioration of GVHD in this study. Therefore, the 'not intensified' strategy was feasible.
On the other hand, there is a therapeutic dilemma as i-TAM is coexistent with GVHD in 30% of the patients. For these patients, GVHD should be treated promptly, but much attention should be paid to deterioration of i-TAM. Novel ways of immunosuppression, which do not cause vascular endothelial damage, are to be sought for these patients in the future.
Rates of complications after diagnostic colonoscopy have been reportedly as low as 0.02%. 28 This study demonstrated that colonoscopic biopsy after allo-HSCT was also safe, if the procedure was performed by expert gastroenterologists with much attention and using plt transfusion for patients with severe thrombocytopenia.
In summary, i-TAM was a major histopathological finding among patients with severe diarrhea. Massive refractory diarrhea and abdominal pain were manifestations of this complication. For patients with i-TAM, avoiding intensification of immunosuppression, which damages vascular endothelium until the resolution of i-TAM, may improve transplant outcome. Prospective trials are warranted to confirm the results, given the limitations of our analysis that include the various timing of biopsy and a possible selection bias for treatment. Our results will provide clues for the etiology and treatment of refractory diarrhea after allo-HSCT.
